March 28, 2019 CSL Behring (the US), a leading global biotherapeutics and biopharmaceutical company, manufacturing plasma-derived and recombinant therapeutic products announced the receiving of an approval from Japan's Ministry of Health, Labour and Welfare has for two of its immunoglobulin therapies - named Hizentra and Privigen for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy
Keywords: Antecedent illness, Guillain-Barre syndrome, Polyradiculoneuropathy
Reduced level of claudin-5 was associated with BNB dysfunction in chronic inflammatory demyelinating polyradiculoneuropathy
(CIDP) (Kanda et al., 2004).
Subtypes were typical acute inflammatory demyelinating polyradiculoneuropathy
(AIDP, n=102, 79.1%), acute motor sensory axonal neuropathy (AMSAN, n=11, 8.5%), acute motor axonal neuropathy (AMAN, n=10, 7.8%), Miller-Fisher syndrome (MFS, n=5, 3.9%), pure sensory subtype (n=1, 0.8%).
(CIDP) as the name suggests is an inflammatory neuropathy of autoimmune aetiology characterised by gradually progressive involvement of sensorimotor nerves.
presenting as increasing abdominal girth.
Neurologic complications such as encephalopathy, optic neuropathy, myelopathy, polyradiculoneuropathy
, and polyneuropathy can be rarely seen after the surgery (1).
(17.) Joint Task Force of the EFNS and the PNS European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy
: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society--First Revision.
(4) Clinically, acute necrotizing vasculitic neuropathy and acute inflammatory demyelination polyradiculoneuropathy
(AIDP) present similarly with symmetric sensorimotor weakness.
Guillain-Barre syndrome (GBS) is a neurological syndrome of autoimmune origin, characterized by an acute inflammatory polyradiculoneuropathy
, which progresses rapidly, triggering an ascending symmetrical muscular weakness.
Less commonly, multifocal mononeuropathy (6-12%), polyradiculoneuropathy
(4-14%), cranial neuropathy (17%), and autonomic neuropathy (50%) can develop [5, 6].
Takahashi et al., "Polyethylene glycol interferon alpha-2b-induced immune-mediated polyradiculoneuropathy
," Internal Medicine, vol.